BioSpace News Archive

Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

StatLab Medical Products (“StatLab”) today announced that it has signed a definitive agreement to purchase Waldemar Knittel Glasbearbeitungs GmbH (“Knittel”), a leading manufacturer of microscope slides and cover glass and provider of engineering consulting services to the broader glass manufacturing industry.

John D. Carpten, Ph.D., chief scientific officer at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, was presented with one of the highest honors in health and medicine when he was elected to the National Academy of Medicine.

In cases where standard therapies fail, an investigational medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.

Two renowned experts from Children’s Hospital of Philadelphia have been elected to the National Academy of Medicine, effective October 1, 2023.

As part of a research study, researchers at Stanford Medicine, Department of Radiology recently began scanning human subjects on GE HealthCare’s novel photon counting CT prototype designed with Deep Silicon detectors, which aims to greatly enhance imaging capabilities and provide clinicians the information and data they need to help enable improved patient outcomes across oncology, cardiology, neurology, and other clinical CT applications.

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.

Meru Health, a technology-enabled digital mental health provider with a novel mind-body approach to mental healthcare, published a peer-reviewed study today in Archives of Suicide Research that reveals an estimated 30% reduction in suicide attempts and death by suicide as well as significant reductions in suicidal ideation.

PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced a very high spectrum of activity of its anti-S. aureus (PP1493 and PP1815) phages against clinical bacterial strains.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2023 financial results will be released after the market closes on Tuesday, November 14, 2023.